Investor Relations

Press Releases

Press Releases
  Date Title and Summary View
Jul 9, 2009
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. — July 9, 2009 — Revance Therapeutics, Inc. (“Revance”) today announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow’s feet wrinkles, demo...
Nov 18, 2008
CONTACT: Revance Therapeutics, Inc. Niquette Hunt Vice President, Marketing & Business Development (510) 742-3400 Newark, Calif. November 18, 2008 — Revance Therapeutics, Inc. (“Revance”) today announced an agreement with Leader Ventures and Horizon Technology Finance that will provide $8 million...
Page: FirstPrevious ...
= add release to Briefcase
Shareholder Tools